MAPT and Alzheimer disease: Exploit the high sensitivity of high plasmon‐coupling nanoplatforms to develop a more effective diagnostic that can distinguish between AD biomarkers (i.e., tau fibrils and amyloid‐β proteins) and whole blood serum